vTv Therapeutics (NASDAQ: VTVT) is a late-stage biopharmaceutical company. It focuses on developing treatments for metabolic diseases. Its main project is cadisegliatin, a new oral therapy being tested for type 1 diabetes.
Before the market opened, vTv Therapeutics reported strong quarterly results. The company announced an earnings per share of $1.65. This figure greatly surpassed the analyst consensus estimate of just $0.21 per share.
The company's revenue performance was also impressive. It reported total revenue of $36.84 million for the period. This result beat the market's expectation of $20.00 million, as highlighted by GlobeNewswire.
vTv Therapeutics is advancing its key Phase 3 CATT1 clinical trial, with enrollment expected to finish in the third quarter of 2026. The company states its strong financial position is enough to fund operations through the trial's data release.
The company's current ratio is 14.36. This metric suggests a strong ability to cover its short-term debts. vTv Therapeutics' price-to-earnings ratio for the last twelve months is 174.48, while its earnings yield is 0.57%.
